Literature DB >> 19561305

Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo.

Caroline Sola1, Pascale André, Céline Lemmers, Nicolas Fuseri, Cécile Bonnafous, Mathieu Bléry, Nicolai R Wagtmann, François Romagné, Eric Vivier, Sophie Ugolini.   

Abstract

Natural killer (NK) cells are lymphocytes of the innate immune system able to recognize and kill tumors lacking self-MHC class I molecules. This "missing-self" recognition is mediated by the lack of engagement of MHC class I-specific inhibitory NK cell receptors that include the killer cell Ig-like receptors (KIR) in humans and Ly49 molecules in mice. A promising immunotherapeutic strategy against MHC class I(+) cancer cells is to block NK cell inhibitory receptors using monoclonal antibodies (mAb). However, interactions between MHC class I molecules and their inhibitory receptors are also required for the acquisition of NK cell functional competence, a process referred as to "education." In addition, inhibitory receptors are involved in self-tolerance on educated NK cells. Here, we developed a preclinical mouse model in which all NK cells are educated by a single transgenic inhibitory receptor, human KIR2DL3, through the engagement with its HLA-Cw3 ligand. This approach revealed that NK cells could be reprogrammed to control the development of mouse syngenic tumors in vivo. Moreover, in vivo anti-KIR mAb treatment induced the killing of HLA(+) target cells without breaking self-tolerance. Finally, the long-term infusion of anti-KIR mAb neither abolished NK cell education nor tumor cell recognition. Therefore, these results strongly support the use of inhibitory receptor blockade in cancer patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19561305      PMCID: PMC2722344          DOI: 10.1073/pnas.0901653106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Natural killer cell acceptance of H-2 mismatch bone marrow grafts in transgenic mice expressing HLA-Cw3 specific killer cell inhibitory receptor.

Authors:  A Cambiaggi; C Verthuy; P Naquet; F Romagné; P Ferrier; R Biassoni; A Moretta; L Moretta; E Vivier
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

Review 2.  Unravelling natural killer cell function: triggering and inhibitory human NK receptors.

Authors:  Lorenzo Moretta; Alessandro Moretta
Journal:  EMBO J       Date:  2003-12-18       Impact factor: 11.598

3.  NK cells: a lesson from mismatched hematopoietic transplantation.

Authors:  Andrea Velardi; Loredana Ruggeri; Lorenzo Moretta
Journal:  Trends Immunol       Date:  2002-09       Impact factor: 16.687

4.  Licensing of natural killer cells by host major histocompatibility complex class I molecules.

Authors:  Sungjin Kim; Jennifer Poursine-Laurent; Steven M Truscott; Lonnie Lybarger; Yun-Jeong Song; Liping Yang; Anthony R French; John B Sunwoo; Suzanne Lemieux; Ted H Hansen; Wayne M Yokoyama
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

5.  Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice.

Authors:  M Bix; N S Liao; M Zijlstra; J Loring; R Jaenisch; D Raulet
Journal:  Nature       Date:  1991-01-24       Impact factor: 49.962

6.  Immunological function of HLA-C antigens in HLA-Cw3 transgenic mice.

Authors:  O Dill; F Kievits; S Koch; P Ivanyi; G J Hämmerling
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

7.  Involvement of HLA class I alleles in natural killer (NK) cell-specific functions: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones displaying a defined specificity (specificity 2).

Authors:  E Ciccone; D Pende; O Viale; A Than; C Di Donato; A M Orengo; R Biassoni; S Verdiani; A Amoroso; A Moretta
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

8.  Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

Authors:  K Kärre; H G Ljunggren; G Piontek; R Kiessling
Journal:  Nature       Date:  1986 Feb 20-26       Impact factor: 49.962

9.  Loss or mismatch of MHC class I is sufficient to trigger NK cell-mediated rejection of resting lymphocytes in vivo - role of KARAP/DAP12-dependent and -independent pathways.

Authors:  Linda Oberg; Sofia Johansson; Jakob Michaëlsson; Elena Tomasello; Eric Vivier; Klas Kärre; Petter Höglund
Journal:  Eur J Immunol       Date:  2004-06       Impact factor: 5.532

10.  Alteration of the natural killer repertoire in H-2 transgenic mice: specificity of rapid lymphoma cell clearance determined by the H-2 phenotype of the target.

Authors:  P Höglund; R Glas; C Ohlén; H G Ljunggren; K Kärre
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

View more
  37 in total

1.  Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.

Authors:  Caroline Veuillen; Thérèse Aurran-Schleinitz; Rémy Castellano; Jérôme Rey; Françoise Mallet; Florence Orlanducci; Laurent Pouyet; Sylvaine Just-Landi; Diane Coso; Vadim Ivanov; Xavier Carcopino; Réda Bouabdallah; Yves Collette; Cyril Fauriat; Daniel Olive
Journal:  J Clin Immunol       Date:  2012-02-09       Impact factor: 8.317

Review 2.  Natural killer cell tolerance: control by self or self-control?

Authors:  Baptiste N Jaeger; Eric Vivier
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-03-01       Impact factor: 10.005

Review 3.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Authors:  Richard W Childs; Mattias Carlsten
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

Review 4.  Investigation of NK cell function and their modulation in different malignancies.

Authors:  Gordana Konjevic; Vladimir Jurisic; Viktor Jovic; Ana Vuletic; Katarina Mirjacic Martinovic; Sandra Radenkovic; Ivan Spuzic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 5.  Targeting natural killer cells and natural killer T cells in cancer.

Authors:  Eric Vivier; Sophie Ugolini; Didier Blaise; Christian Chabannon; Laurent Brossay
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

6.  Adoptive Immunotherapy after Allogeneic Hematopoietic Progenitor Cell Transplantation: New Perspectives for Transfusion Medicine.

Authors:  Susanne Hofmann; Jochen Greiner
Journal:  Transfus Med Hemother       Date:  2011-05-11       Impact factor: 3.747

7.  Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

Authors:  Holbrook E Kohrt; Ariane Thielens; Aurelien Marabelle; Idit Sagiv-Barfi; Caroline Sola; Fabien Chanuc; Nicolas Fuseri; Cécile Bonnafous; Debra Czerwinski; Amanda Rajapaksa; Erin Waller; Sophie Ugolini; Eric Vivier; François Romagné; Ronald Levy; Mathieu Bléry; Pascale André
Journal:  Blood       Date:  2013-12-10       Impact factor: 22.113

8.  NK cell maturation and function in C57BL/6 mice are altered by caloric restriction.

Authors:  Jonathan F Clinthorne; Eleni Beli; David M Duriancik; Elizabeth M Gardner
Journal:  J Immunol       Date:  2012-12-14       Impact factor: 5.422

Review 9.  Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).

Authors:  Amanda K Purdy; Kerry S Campbell
Journal:  Cancer Biol Ther       Date:  2009-12-28       Impact factor: 4.742

Review 10.  NK cell-based immunotherapy for malignant diseases.

Authors:  Min Cheng; Yongyan Chen; Weihua Xiao; Rui Sun; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2013-04-22       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.